Phytoestrogen α-zearalanol ameliorates memory impairment and neuronal DNA oxidation in ovariectomized mice

Dong, Yilong; Wang, Yanmei; Liu, Y; Yang, Nan; Zuo, Pingping

doi:10.6061/clinics/2013(09)13

Cited by 11 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studied in different cell lines, ZEN exhibited competitive inhibitor properties on aromatase or CIP19, inhibiting the biosynthesis of estrogen [ 16 ]. On the other hand, other studies reported the positive effects of ZEN on hippocampal neurogenesis and cognitive improvement in ovariectomized mice and rats, similar to those caused by 17β-estradiol (E2) [ 17 , 18 , 19 ]. The neuroprotective effects of ZEN metabolites were also demonstrated in cultured primary hippocampal neurons exposed to amyloid-β peptide (25–35) [ 20 ].…”

Section: Introductionmentioning

confidence: 98%

Comparative Analysis of Zearalenone Effects on Thyroid Receptor Alpha (TRα) and Beta (TRβ) Expression in Rat Primary Cerebellar Cell Cultures

Kiss

Ioja

Tóth

et al. 2018

IJMS

View full text Add to dashboard Cite

Thyroid receptors play an important role in postnatal brain development. Zearalenone (ZEN), a major mycotoxin of Fusarium fungi, is well known to cause serious health problems in animals and humans through various mechanisms, including the physiological pathways of thyroid hormone (TH). In the present study, we aimed to investigate the expression of thyroid receptors α (TRα) and β (TRβ) in primary cerebellar neurons in the presence or absence of glia and following ZEN treatment, using quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and Western blot. Primary cerebellar granule cells were treated with low doses of ZEN (0.1 nM) in combination with physiologically relevant concentrations of l-thyroxine (T4), 3,3′,5-triiodo-l-thyronine (T3) and 17β-estradiol (E2). Expression levels of TRα and TRβ at mRNA and protein levels were slightly modified by ZEN administered alone; however, along with thyroid and steroid hormones, modelling the physiological conditions, expression levels of TRs varied highly depending on the given treatment. Gene expression levels were also highly modulated by the presence or absence of glial cells, with mostly contrasting effects. Our results demonstrate divergent transcriptional and translational mechanisms involved in the expression of TRs implied by ZEN and hormonal milieu, as well as culturing conditions.

show abstract

Section: Introductionmentioning

confidence: 98%

Comparative Analysis of Zearalenone Effects on Thyroid Receptor Alpha (TRα) and Beta (TRβ) Expression in Rat Primary Cerebellar Cell Cultures

Kiss

Ioja

Tóth

et al. 2018

IJMS

View full text Add to dashboard Cite

show abstract

“…Dong et al. () evaluated the effect of α‐ZAL on Alzheimer's disease‐related memory impairment and neuronal oxidation in ovariectomised female mice exposed to equivalent doses of 17β‐oestradiol or α‐ZAL for 8 weeks. Mice received i.p.…”

Section: Toxicitymentioning

confidence: 99%

Appropriateness to set a group health‐based guidance value for zearalenone and its modified forms

Hoogenboom¹

2016

EFS2

View full text Add to dashboard Cite

The current tolerable daily intake (TDI) for zearalenone (ZEN) of 0.25 lg/kg body weight (bw) per day established by the EFSA Panel for Contaminants in the Food Chain (CONTAM Panel) in 2011 is based on oestrogenicity in pigs. No new studies were identified to change this TDI. The modified forms of ZEN identified are phase I and phase II metabolites. Phase I metabolites are mainly formed through reduction. Phase II metabolites are formed by conjugation of ZEN and its phase I metabolites with glucose or sulfate, and in animals glucuronic acid. The few data on the occurrence of modified forms of ZEN indicated that cereal-based foods are the main source, containing amounts varying from a few up to 100% of ZEN. Most of the phase I metabolites have oestrogenic activity and it is assumed that their combined action will be additive. The CONTAM Panel found it appropriate to set a group TDI of 0.25 lg/kg bw per day expressed as ZEN equivalents for ZEN and its modified forms (phase I and phase II metabolites). To account for differences in in vivo oestrogenic potency, each phase I metabolite was assigned a potency factor relative to ZEN to be applied to exposure estimates of the respective ZEN metabolites. It was assumed that conjugates (phase II metabolites) of ZEN and its phase I metabolites, which per se have no oestrogenic activity, will be cleaved releasing ZEN and its phase I metabolites. These conjugates were assigned the same relative potency factors as their aglycones. The overall uncertainty associated with the present assessment is considered as high. It would rather overestimate than underestimate any risk of modified ZEN. Several aspects of the uncertainty could be reduced provided more data are made available on oestrogenicity of modified ZEN, in particular a-zearalenol, in pigs.

show abstract

Zearalenone as an endocrine disruptor in humans

Kowalska

Habrowska-Górczyńska

Piastowska-Ciesielska

2016

Environmental Toxicology and Pharmacology

185

127

View full text Add to dashboard Cite

Phytoestrogen α-zearalanol ameliorates memory impairment and neuronal DNA oxidation in ovariectomized mice

Cited by 11 publications

References 29 publications

Comparative Analysis of Zearalenone Effects on Thyroid Receptor Alpha (TRα) and Beta (TRβ) Expression in Rat Primary Cerebellar Cell Cultures

Comparative Analysis of Zearalenone Effects on Thyroid Receptor Alpha (TRα) and Beta (TRβ) Expression in Rat Primary Cerebellar Cell Cultures

Appropriateness to set a group health‐based guidance value for zearalenone and its modified forms

Zearalenone as an endocrine disruptor in humans

Contact Info

Product

Resources

About